Chung-Pa-Juhn(Chung-Pa-Juhn) - 药物靶点：MMPs_在研适应症：骨关节炎_专利_临床

概要

基本信息

药物类型

中药

别名

GCSB、Shinbaro

+ [1]

靶点

MMPs

作用方式

抑制剂

作用机制

MMPs抑制剂(基质金属蛋白酶家族抑制剂)

治疗领域

皮肤和肌肉骨骼疾病

在研适应症

骨关节炎

非在研适应症-

原研机构

Green Cross Holdings Corp.

在研机构

Green Cross Holdings Corp.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2014-04-23),

骨关节炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Chung-Pa-Juhn 相关的临床试验

NCT01910116

/ Completed临床2/3期IIT

Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.

GCSB-5 ("Shinbaro capsule"), is a mixture of 6 oriental herbs that have anti-inflammatory and analgesic effects along with an excellent safety profile. This study is aimed at investigating efficacy of Shinbaro in the treatment of hand osteoarthritis which needs a long term treatment in a placebo controlled, double-blind randomized trial.

开始日期2013-09-01

申办/合作机构

Seoul National University Hospital

[+1]

NCT01604239

/ Completed临床4期

A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of 'Shinbaro Capsule' Compared With Historical Data of 'Celebrex Capsule' in Patients With Osteoarthritis

This study investigates if Shinbaro capsule has a lower incident of gastrointestinal events than celecoxib in subjects with osteoarthritis.

开始日期2012-05-01

申办/合作机构

Green Cross Co., Ltd.

NCT01535417

/ Completed临床3期

A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee

The purpose of this study is to evaluate the efficacy and safety of 'Shinbaro Capsule', a new herbal anti-arthritic agent, in patients with osteoarthritis of the knee.

开始日期2009-05-01

申办/合作机构

Green Cross Co., Ltd.

100 项与 Chung-Pa-Juhn 相关的临床结果

登录后查看更多信息

100 项与 Chung-Pa-Juhn 相关的转化医学

登录后查看更多信息

100 项与 Chung-Pa-Juhn 相关的专利（医药）

登录后查看更多信息

17

项与 Chung-Pa-Juhn 相关的文献（医药）

2024-02-01·Current Rheumatology Reviews

Efficacy of Herbal Medicine in Hand Osteoarthritis: A Narrative Review

Review

作者: Noorabadi, Parisa ; Aghili, Seyedeh Mehrnaz ; Sahebari, Maryam ; Salari, Masoumeh

Objective:Osteoarthritis (OA) is one of the most prevalent joint disorders in the world that has placed an enormous economic and social burden on governments and healthcare sectors in many countries. Hand OA (HOA) is the most common peripheral arthritis, which is less investigated than knee and hip OA. Due to limited approved drug choices and adverse effects of long-term use of current regimens, we aimed to review the existing evidence that were used as oral herbal medicine to treat HOA.Methods:The PubMed database was searched for both observational and interventional studies that have investigated herbal medicine safety and efficacy in HOA, written in English and published between 2010 and 2022.Results:A total of 5 original articles fulfilled the inclusion criteria, and each article assessed a different herbal regimen. Overall, it seems desirable to add specific herbal treatments to the regimen of HOA patients, specifically in case of early stages of HOA.Conclusion:Currently, the need for a low-risk alternative treatment in HOA patients is felt more than ever. There are reliable references relating to the safety of Korean red ginseng, GCSB-5, XLGB, and GS-GCu in these patients, although their efficacy was limited. Additionally, herbs like curcumin and Boswellia serrata have positively affected patients with knee osteoarthritis. However, there is a lack of strong evidence supporting their effectiveness in hand osteoarthritis (HOA). This emphasizes the potential benefits that these herbs may have for HOA patients.

2023-12-01·Archives of Rheumatology

GCSB-5 regulates inflammatory arthritis and pain by modulating the mitogen-activated protein kinase signaling pathway in a murine model of rheumatoid arthritis

Article

作者: Bang, Jihye ; Young Park, Soo ; Kim, Sang-Hyon ; Kim, Gyeonghwa ; Kim, Ji-Min ; Jung, Hye Ra

Objectives: This study aimed to determine whether GCSB-5 has anti-inflammatory and antinociceptive effects in mice with collagen-induced arthritis (CIA), an animal model of rheumatoid arthritis (RA), and investigate the influence of GCSB-5 on the mitogen-activated protein kinase (MAPK) pathway.Materials and methods: The experimental animal study was designed to include five groups: CIA mice treated with GCSB-5 (300 mg/kg), GCSB-5 (600 mg/kg), celecoxib (60 mg/kg), or saline for four weeks, and nontreated control mice. The clinical severity of arthritis was scored. Nociceptive thresholds were measured by using a von Frey dynamic plantar analgesimeter. The MAPK pathway was evaluated in mouse synovium. The expression of channels associated with pain signaling was assessed by western blot and immunohistochemical staining.Results: GCSB-5 treatment diminished the severity of clinical arthritis and increased the nociceptive threshold in mice with CIA. Celecoxib, a positive control drug, also showed comparable changes. Clinical arthritis scores were inversely related to mechanical thresholds. GCSB-5 administration decreased the levels of anti-type II collagen antibody and inflammatory cytokines in the sera of mice with CIA. Furthermore, ERK, p38 MAPK, and JNK phosphorylation were downregulated and TRPV1 and ASIC3 expression were decreased in the synovium of GCSB-5-treated mice compared to salinetreated mice. Interleukin-6-induced TRPV1 and ASIC3 upregulation were also inhibited by GCSB-5 in human RA fibroblast-like synoviocytes in vitro.Conclusion: GCSB-5 decreased inflammatory arthritis and pain in a murine model of RA. The results present evidence that GCSB-5 may be beneficial for relieving pain as well as decreasing inflammation in autoimmune arthritis, such as RA.

2023-01-01·Chemosphere

Vitamin C modified crayfish shells biochar efficiently remove tetracycline from water: A good medicine for water restoration

Article

作者: Dai, Yingjie ; Jiang, Huating

In this study, crayfish shell biochar (CSB) was modified by introducing vitamin C (VC) with abundant surface functional groups. CSB was impregnated with VC at different ratios and its capacity to adsorb tetracycline (TC) from water was analyzed. The physicochemical properties of CSB were determined by N₂ adsorption-desorption isotherm analysis, X-ray diffraction, and Fourier transform infrared spectroscopy. The effects of various factors on adsorption such as the pH, TC concentration, time, and salt ion concentrations were also investigated. Based on the chemical structure of VC, VC can provide CSB with more oxygen-containing functional groups such as hydroxyl groups. The results showed that the CSB modified with VC (CSB-VC) exhibited excellent adsorption of TC, and CSB-VC₂ with an impregnation ratio of 2 (gVC/gCSB) had the greatest adsorption performance (saturated adsorption capacity, Q_m = 293.36 mg/g), whereas the adsorption performance of CSB alone was about 50% lower (Q_m = 172.16 mg/g). The optimal impregnation ratio VC improved the adsorption performance of CSB after modification to 70.4% of the original. Hydrogen bonding, p-p conjugation, pi-pi electron donor-acceptor effect, and π-π interactions were identified as the main adsorption mechanisms. CSB-VC₂ was highly effective over a wide range of pH values and at high ion concentrations. Experiments demonstrated the effective regeneration of the adsorbent after multiple cycles, thereby indicating its excellent reusability. It should be noted that the adsorption capacity was good under different water quality conditions, and thus it should exhibit stable adsorption performance under complex water environment conditions.

100 项与 Chung-Pa-Juhn 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	M09AX	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	韩国	Green Cross Holdings Corp.	2014-04-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01604239 (Pubmed \| J Ethnopharmacol)	临床4期	骨关节炎	761	GCSB-5	膚簾齋鏇獵廠獵構顧淵(範糧簾網簾憲窪簾築鬱) = 範廠鑰鹽廠遞壓衊獵膚鹽廠淵餘遞鹹餘選製夢 (獵淵簾憲艱鬱憲鬱蓋鹹 )	积极	2016-08-02
NCT01910116 (Pubmed \| Med Lett Drugs Ther \| Clin Ther) 人工标引	临床2/3期	骨关节炎	215	GCSB-5	(壓鹽觸餘蓋膚築遞鹽壓) = 鏇鏇鏇願衊範襯壓壓獵鹽鬱顧壓齋鏇獵齋淵繭 (壓遞餘網餘構顧鹹網築 ) 更多	积极	2016-08-01
				Placebo	(壓鹽觸餘蓋膚築遞鹽壓) = 製積醖窪憲積網淵鬱願鹽鬱顧壓齋鏇獵齋淵繭 (壓遞餘網餘構顧鹹網築 ) 更多
NCT01910116 (CTgov)	临床2/3期	骨关节炎	220	Shinbaro (Shinbaro)	鏇構簾繭淵築積願遞蓋(構襯鏇製蓋願廠鹹餘積) = 醖積窪蓋夢獵窪壓鹹遞醖醖選鑰醖糧壓鹽遞顧 (淵網積製夢製憲顧願製, 廠築蓋艱淵範鹹襯鑰艱 ~ 鑰醖齋顧艱構製夢糧獵) 更多	-	2015-12-17
				Placebo (Placebo)	鏇構簾繭淵築積願遞蓋(構襯鏇製蓋願廠鹹餘積) = 觸衊廠製網窪衊範餘網醖醖選鑰醖糧壓鹽遞顧 (淵網積製夢製憲顧願製, 鏇襯鹽鏇簾窪窪簾廠鬱 ~ 繭餘鏇齋糧夢鏇遞觸蓋) 更多
NCT01910116 (EULAR2015)	临床2/3期	骨关节炎	-	GCSB-5 600 mg	(繭構鹽窪範構簾鏇繭製) = 糧鹹鹽簾糧夢範鹽鏇製鑰襯顧膚獵蓋夢餘齋遞 (壓鑰網膚製構網願觸鬱, -23.8 ~ -0.2) 更多	积极	2015-06-10
				Placebo	(繭構鹽窪範構簾鏇繭製) = 選築糧繭選觸衊積積齋鑰襯顧膚獵蓋夢餘齋遞 (壓鑰網膚製構網願觸鬱, -16.7 ~ 6.0) 更多